Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.81 |
| ▸ | DPP7 | Q9UHL4 | 17/20 | 0.81 |
| ▸ | DPP8 | Q6V1X1 | 13/20 | 0.81 |
| ▸ | FAP | Q12884 | 12/20 | 0.81 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 0.81 |
| ▸ | PITRM1 | Q5JRX3 | 4/20 | 0.76 |
| ▸ | PREP | P48147 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747119 | 1.00 | DPP4 (0.81) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL12657193 | 0.89 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL16079845 | 0.89 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL18828991 | 0.89 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL16921202 | 0.89 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL21156682 | 0.87 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL21156220 | 0.87 | DPP4 (0.84) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL21746373 | 0.87 | DPP4 (1.00) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL12657191 | 0.85 | DPP4 (0.76) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL21746912 | 0.84 | DPP4 (0.74) | DPP4DPP7DPP8FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | DPP4 1251/4885DPP7 910/4885DPP8 904/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | DPP4 1251/4885DPP7 910/4885DPP8 904/4885 |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | DPP4 1251/4885DPP7 910/4885DPP8 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.